United States Liquid Biopsy Market Overview
Base Year: 2024
Historical Years: 2019–2024
Forecast Years: 2025–2033
Market Growth Rate: 13.6% (2025–2033)
The United States liquid biopsy market is growing due to advancements in non-invasive cancer diagnostics, increasing adoption of personalized medicine, and rising demand for early disease detection. The U.S. liquid biopsy market size was valued at USD 563.6 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,775.8 Million by 2033, exhibiting a CAGR of 13.6% from 2025-2033.
United States Liquid Biopsy Industry Trends and Drivers:
The United States liquid biopsy market is changing quickly. This shift is due to better diagnostic technologies and a rising need for non-invasive tests. Liquid biopsies are a strong alternative to traditional tissue biopsies. They can detect cancer-related markers in blood samples. This method eases patient discomfort and enables real-time tracking of tumors and treatment responses. As cancer cases rise, healthcare providers increasingly use liquid biopsies for better early detection and tailored treatment plans. Advanced genomic sequencing technologies drive market growth by allowing more precise analyses of circulating tumor DNA.
However, the U.S. liquid biopsy market faces challenges. Regulatory hurdles and the need for thorough clinical validation are key issues. Since this field is still new, regulatory bodies are working on guidelines for liquid biopsy tests. It's also vital to ensure results are reliable and reproducible to gain trust from clinicians and patients. To meet these challenges, stakeholders are pouring resources into research and development. They want to validate liquid biopsy technologies and show their clinical value. Partnerships between academic institutions, healthcare providers, and industry players are key for driving innovation. They help expand the use of liquid biopsies in cancer care. As awareness of liquid biopsies grows, the market is poised for significant growth. This growth is fueled by technological advances and a rising demand for personalized medicine.
Grab a sample PDF of this report: https://www.imarcgroup.com/united-states-liquid-biopsy-market/requestsample
United States Liquid Biopsy Industry Segmentation:
The report has segmented the market into the following categories:
Analysis by Product and Service:
- Kits and Reagents
- Platforms and Instruments
- Services
Analysis by Circulating Biomarker:
- Circulating Tumor Cells
- Extracellular Vesicles
- Circulating Tumor DNA
- Others
Analysis by Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
Analysis by End User:
- Hospitals and Laboratories
- Academic and Research Centers
- Others
Regional Analysis:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key highlights of the Report:
- Market Performance (2019–2024)
- Market Outlook (2025–2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145
Comments
0 comment